The Relative Clinical and Economic Value of Ipilimumab in the Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases from a Brazilian Private Health Care System Perspective
Abstract
Authors
S Stefani S Tanaka R Araujo K Chagas G Bernardino BM Donato